NCT00050323View on ClinicalTrials.gov

Safety/Efficacy of a Vaccine Prepared From Dendritic Cells Combined With Tumor Cells to Treat Advanced Kidney Cancer

PHASE1/PHASE2CompletedINTERVENTIONAL
Enrollment

30

Participants

Timeline

Start Date

November 30, 2002

Study Completion Date

March 31, 2004

Conditions
Carcinoma, Renal Cell
Interventions
DRUG

Allogeneic DCs and Autologous RCC Tumor Derived Cells

Trial Locations (4)

44195

The Cleveland Clinic Foundation, Cleveland

90095

UCLA Medical Center, Los Angeles

02215

Beth Israel Deaconess Medical Center, Boston

Dana Farber Cancer Institute (DFCI), Boston

All Listed Sponsors
lead

Genzyme, a Sanofi Company

INDUSTRY

NCT00050323 - Safety/Efficacy of a Vaccine Prepared From Dendritic Cells Combined With Tumor Cells to Treat Advanced Kidney Cancer | Biotech Hunter | Biotech Hunter